- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02299011
Comparison of Biomatrix and Orsiro Drug Eluting Stent (BIODEGRADE)
Comparison of Biomatrix and Orsiro Drug Eluting Stent in Angiographic Result in Patients With All-comer Patients With Coronary Artery Disease : A Multicenter, Randomized, Open Label Study (BIODEGRADE Study)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The rate of in-stent restenosis after percutaneous coronary intervention (PCI) has decreased since the launching of drug-eluting stents (DES). However, restenosis still remains a problem since PCI is being performed on more complex, calcified, tortuous and tough lesions. Furthermore, there is still a controversy on whether these DES are more thrombogenic than bare metal stent (BMS) because of inflammation related to the polymer coating and delayed vessel healing due to the eluted drug despite of reduced restenosis. Therefore, works aiming to reduce both restenosis and thrombotic event are still on-going in the field of interventional cardiology, and there has been a rush of various third generation DES with "biodegradable polymer". Recently, Orsiro hybrid DES (Biotronik AG, Bulach, Switzeland) has been developed. The Orsiro DES incorporated optimally combined two kind of polymer onto thinner cobalt-chromium backbone (60um) compared with earlier type of DES. The BIOlute® active component is a bioabsorbable polymer matrix combined with an anti-proliferative drug, sirolimus, that is released in a controlled manner leaving only the PROBIO® coated stent in the long-term. The PROBIO® passive coating encapsulates the stent and eliminates interaction between the metal stent and the surrounding tissue. To date, Orsiro stent showed excellent results in terms of late lumen loss at 9 months in first-in-man single arm trial comparing the historical results of other DES (BIOFLOW-I trial), and RCT with non-inferiority design, comparing late lumen loss at 9 months of Orsiro versus everolimus-eluting stent (Xience prime®) is ongoing (BIOFLOW-II trial). However, there have been no trials comparing the Orsiro stent versus the Biomatrix stent (Biosensors Inc, Newport Beach, CA, USA).
This multicenter, randomized, open label, parallel arm study will evaluate whether the innovative newer generation stent, Orsiro hybrid DES, is non-inferior to the third generation stent, Biomatrix stent, in terms of 18 months late lumen loss.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Gyeonggi
-
Seongnam, Gyeonggi, Korea, Republic of, 463-707
- Seoul National Universtiy Bundang Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
General Inclusion Criteria
- Subject must be at least 18 years of age.
- Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving the Biomatrix flex stents or Orsiro stents, and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure.
- Subject must have significant lesion (>50% by visual estimate) in any of the coronary arteries, venous or arterial bypass grafts.
- Subject must have evidence of myocardial ischemia (e.g., stable, unstable angina, recent infarction, silent ischemia, positive functional study or a reversible changes in the electrocardiogram (ECG) consistent with ischemia). In subjects with diameter stenosis > 70%, evidence of myocardial ischemia does not have to be documented.
Angiographic Inclusion Criteria
- Target lesion(s) must be located in coronary artery, venous or arterial bypass graft with diameter of ≥ 2.5 mm and ≤ 4.5 mm.
- Target lesion(s) must be amenable for percutaneous coronary intervention.
Exclusion Criteria:
- The patient has a known hypersensitivity or contraindication to any of the following medications: Heparin, Aspirin, Clopidogrel, Cilostazol, Prasugrel, Ticagrelor, Biolimus, Sirolimus, Contrast media (Patients with documented sensitivity to contrast media which can be effectively premedicated with steroids and diphenhydramine [e.g. rash] may be enrolled. Those with true anaphylaxis to prior contrast media, however, should not be enrolled.)
- Systemic (intravenous) Biolimus or Sirolimus use within 12 months.
- Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study.
- History of bleeding diathesis, known coagulopathy (including heparin- induced thrombocytopenia), abnormal hemogram (Hb<10g/dL or PLT count <100,000/μL) or will refuse blood transfusions
- Patients with severe LV systolic dysfunction (LVEF<25%) or cardiogenic shock
- Gastrointestinal or genitourinary bleeding within the prior 2 months, or major surgery within 2 months.
- Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment).
- Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow- up period.
- Symptomatic heart failure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Orsiro drug eluting stent
|
Orsiro Hybrid drug eluting stent
Other Names:
|
Active Comparator: Biomatrix drug eluting stent
|
Biomatrix Flex drug eluting stent
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Target lesion failure (TLF)
Time Frame: 18 months
|
TLF is a composite of cardiac death, target vessel-related myocardial infarction and ischemia-driven target lesion revascularization as measured by percent of participants with adverse events
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All death
Time Frame: 18 months
|
All-cause death as measured by percent of participants with adverse events
|
18 months
|
All death
Time Frame: 36 months
|
All-cause death as measured by percent of participants with adverse events
|
36 months
|
Cardiac death
Time Frame: 18 months
|
cardiac death as measured by percent of participants with adverse events
|
18 months
|
Cardiac death
Time Frame: 36 months
|
cardiac death as measured by percent of participants with adverse events
|
36 months
|
Target vessel-related MI and all MI
Time Frame: 18 months
|
Target vessel-related MI and all MI as measured by percent of participants with adverse events subdivided as q wave and non-q wave
|
18 months
|
Target vessel-related MI and all MI
Time Frame: 36 months
|
Target vessel-related MI and all MI as measured by percent of participants with adverse events subdivided as q wave and non-q wave
|
36 months
|
Stent thrombosis
Time Frame: 18 months
|
Stent thrombosis (definite/possible/probable) as measured by percent of participants with adverse events
|
18 months
|
Stent thrombosis
Time Frame: 36 months
|
Stent thrombosis (definite/possible/probable) as measured by percent of participants with adverse events
|
36 months
|
Net clinical outcome including bleeding (major and minor) as measured by percent
Time Frame: 18 months
|
Net clinical outcome including bleeding (major and minor) as measured by percent of participants with adverse events
|
18 months
|
Net clinical outcome including bleeding (major and minor) as measured by percent
Time Frame: 36 months
|
Net clinical outcome including bleeding (major and minor) as measured by percent of participants with adverse events
|
36 months
|
In-stent & In-segment late loss
Time Frame: 18 months
|
In-stent & In-segment late loss as measure by post-PCI and F/U QCA
|
18 months
|
In-stent & In-segment late loss
Time Frame: 36 months
|
In-stent & In-segment late loss as measure by post-PCI and F/U QCA
|
36 months
|
In-stent & In-segment % diameter stenosis
Time Frame: 18 months
|
In-stent & In-segment % diameter stenosis as measure by post-PCI and F/U QCA
|
18 months
|
In-stent & In-segment % diameter stenosis
Time Frame: 36 months
|
In-stent & In-segment % diameter stenosis as measure by post-PCI and F/U QCA
|
36 months
|
Degree of stent strut endothelialization and malapposition on OCT
Time Frame: 18 months
|
Degree of stent strut endothelialization and malapposition on OCT as measure by post-PCI and F/U OCT analysis
|
18 months
|
Degree of stent strut endothelialization and malapposition on OCT
Time Frame: 36 months
|
Degree of stent strut endothelialization and malapposition on OCT as measure by post-PCI and F/U OCT analysis
|
36 months
|
Target lesion failure (TLF)
Time Frame: 36 months
|
TLF is a composite of cardiac death, target vessel-related myocardial infarction and ischemia-driven target lesion revascularization as measured by percent of participants with adverse events
|
36 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: In-Ho Chae, MD, Seoul National University Bundang Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- B1403-244-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Ischemia
-
Recardio, Inc.CompletedAcute Myocardial Infarction | STEMI - ST Elevation Myocardial Infarction | Acute Myocardial IschemiaNetherlands, Hungary, Austria, Poland, Belgium
-
University of Roma La SapienzaCompletedRosuvastatin in Preventing Myonecrosis in Elective Percutaneous Coronary Interventions (PCIs) (ROMA)Periprocedural Myocardial NecrosisItaly
-
Lokien van NunenMaquet Cardiovascular; Stichting Toegepaste Wetenschappen (project number 11052)CompletedAcute Myocardial Infarction | Persisting Ischemia | No ReflowNetherlands
-
University Hospital "Sestre Milosrdnice"CompletedSTEMI - ST Elevation Myocardial Infarction | Myocardial ReperfusionCroatia
-
Tomsk National Research Medical Center of the Russian...CompletedMyocardial Infarction | Myocardial Injury | STEMI | Myocardial NecrosisRussian Federation
-
Fundacio Privada Mon Clinic BarcelonaMiracor Medical SANot yet recruiting
-
University Hospital, ToulouseThoratec CorporationWithdrawnChronic Myocardial IschemiaFrance
-
Deutsches Herzzentrum MuenchenCompletedInfarction, MyocardialGermany
-
Barts & The London NHS TrustUniversity College, London; Queen Mary University of LondonCompletedAcute Myocardial InfarctionSwitzerland, Denmark, United Kingdom
-
Tehran University of Medical SciencesRecruitingMyocardial Infarction | Myocardial Ischemia | Myocardial StunningIran, Islamic Republic of
Clinical Trials on Orsiro drug eluting stent
-
Biotronik AGCompletedCoronary Artery DiseaseRomania
-
Seung-Jung ParkCardioVascular Research Foundation, Korea; Biotronik Korea Co., LtdCompletedCoronary Artery Disease | Angioplasty, Transluminal, Percutaneous CoronaryKorea, Republic of
-
Chang Gung Memorial HospitalNot yet recruitingVascular Response of Orsiro vs. Xience Drug-Eluting Stents for Treating Coronary Bifurcation LesionsCoronary Artery DiseaseTaiwan
-
Yonsei UniversityCompletedPercutaneous Coronary Intervention | All-comerKorea, Republic of
-
Thorax Centrum TwenteUnknownCoronary Artery Disease | Angina Pectoris | Acute Coronary Syndrome | Unstable Angina Pectoris | Coronary Stenosis | Coronary RestenosisNetherlands, Israel, Belgium
-
Henan Institute of Cardiovascular EpidemiologyRecruiting
-
Odense University HospitalUnknownCoronary Artery Disease | Ischemic Heart DiseaseDenmark
-
Fatebenefratelli and Ophthalmic HospitalCompletedCardiovascular Diseases
-
Aarhus University Hospital SkejbyMedtronic Cardiovascular; Biosensors InternationalCompletedCoronary Artery Disease | Angina PectorisDenmark
-
Hospital Universitari Vall d'Hebron Research InstituteB.Braun Surgical SACompleted